While these studies suggest potential benefits, they do not provide the level of evidence needed to confirm safety and efficacy in humans
Furthermore, the option to continue or initiate new AD medication during the trial, including the amyloid lowering monoclonal antibodies, was not a randomization stratification factor and may therefore act as a confounding factor if their use across treatment arms is unequal
GLP-1 receptors in the gut mediate gastric emptying, intestinal motility, and nausea signaling
What matters is the clinical outcome at the respective maximum doses
Fourth, the analyses with dementia subtypes should be considered exploratory and interpreted with caution, because the diagnoses were not necessarily biomarker-confirmed, and the referent standard in the validation studies [38, 39] was not biomarker-confirmed diagnoses
In general, most new users start with a lower dose and monitor side effects over the first several weeks of use